Pronota Company

Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
Technology: P4 Medicine
Industry: Biotechnology, Health Care, Science and Engineering
Headquarters: Ghent, Oost-Vlaanderen, Belgium
Founded Date: 2004-10-18
Employees Number: 11-50
Funding Status: Late Stage Venture
Investors Number: 10
Total Funding: $41.2M
Estimated Revenue: $1M to $10M
Last Funding Type: Series C

Visit Website
info@pronota.com
https://www.twitter.com/mycartis
Register and Claim Ownership